Vaccines

New 21-valent conjugate vaccine authorized to combat invasive pneumococcal disease and pneumonia in individuals aged 18 and older.

In the second installment of our interview with Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), he discusses some of the takeaways in how public health messaging was lost on the public, which lead to mistrust, and thus leaving open the door for disinformation and misinformation.

David Wohl, MD, explains the health risks of visceral fat and the role of treatments like Tesamorelin F8 in managing the condition.

Heather Platt, MD, discusses Merck’s ongoing research into real-world effectiveness and cost-effectiveness and offers a preview of data to be presented at ESCMID 2025.

In the second installment of our COVID-19 pandemic series, Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), discusses the paradox that has arisen from the COVID-19 vaccines that in spite of their development in record time, what remains is a deeper mistrust in immunizations overall.

Onyema Ogbuagu, MBBCh, FACP, FIDSA discussed 96% virologic suppression with lenacapavir-based therapy, showing similar results to daily oral regimens.

The vaccine is based on an attenuated rabies vaccine that was subsequently inactivated to make the vaccine candidate. The National Institutes of Health (NIH) is sponsoring the trial.

Cases in the US continue to increase, and a new analysis shows 2024 was the highest year for measles cases in Europe in 25 years.

Phase 1 data on VH184, a third-generation integrase strand transfer inhibitor, and VH499, a novel HIV-1 capsid inhibitor, highlighting their antiviral potency, safety profiles, and potential for long-acting injectable formulations.

New pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention

Phase 1b trial data demonstrated immune response, with 85% reduction in viral shedding and robust mucosal immunity in elderly adults.

The phase 1/2a trial of BioNTech's BNT165e vaccine, involving nearly 180 participants, faces delays as global malaria control efforts struggle with funding and political uncertainties.

Approved vaccines for chikungunya, meningococcal disease, updates on HIV prevention, key regulatory decisions, and more.

The interim results demonstrated a slightly better vaccine effectiveness in individuals who are immunocompetent vs immunocompromised individuals.

The most recent CDC report accounts for 33 million flu illnesses, 430,000 hospitalizations, and 19,000 deaths this flu season, with Influenza A(H1N1) and A(H3N2) as the primary strains.

The World Health Organization (WHO) reports on the vaccine uptake in that region, and the Global Polio Eradication Initiative reports that some countries recording new cases.

A new study published in JAMA Network Open points out that immunization also occurred in individuals who did not receive routine prenatal or infant vaccines.

Confirmed measles cases in Texas have risen from 24 to 58 in just six days, with 13 hospitalizations reported.

The company's trivalent vaccine (mRNA-1403) was being studied in a phase 3 trial.

In a statement, the official, Ralph Abraham, MD, along with the state’s deputy surgeon general, wrote that because of “COVID missteps” they will no longer encourage vaccination to people.

In the Phase 3 trial, GSK's vaccine met all 11 primary endpoints, providing expanded options for preventing invasive meningococcal disease in individuals aged 10-25 years.

The approval is based on positive phase 3 clinical trial results, offering an effective option for travelers and others at risk of chikungunya, the mosquito-borne illness.

Su H Wang, MD, FACP, MPH discusses combating vaccine misinformation, preventing outbreaks, and highlighting global health interconnectedness

Heather Platt, MD, discusses Merck’s latest achievement with Capvaxive and its potential to significantly reduce invasive pneumococcal disease and pneumonia in high-risk adult populations across Europe.

The association’s Executive Director Georges Benjamin, MD, offers some commentary as to why they have concerns around him as Health and Human Services Secretary.